Ra Pharmaceuticals, Inc. (NASDAQ: RARX) today announced that it has initiated dosing in the Company’s global Phase 2 clinical program ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE